Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Short-Term Debt repayments (2021 - 2022)

Aytu Biopharma has reported Short-Term Debt repayments over the past 2 years, most recently at $30.5 million for Q3 2022.

Quarterly Short-Term Debt repayments fell 33.11% to $30.5 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $163.5 million through Sep 2022, changed N/A year-over-year, with the annual reading at $156.4 million for FY2022, 189.66% up from the prior year.
Short-Term Debt repayments was $30.5 million for Q3 2022 at Aytu Biopharma, down from $39.3 million in the prior quarter.
Over five years, Short-Term Debt repayments peaked at $48.0 million in Q2 2021 and troughed at $30.5 million in Q3 2022.